| abstract |
The present invention relates to new compounds of formula (I) wherein Y1 and Y2 selected from the group consisting of hydrogen, halogen atom, C1-4 alkyl, C1-4 alkoxy or cyano group, X is oxygen or two hydrogen atoms; Z is -(CH2)n- group or S; n is 1 or 2; R is selected from the group consisting of optionally substituted C1-7 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-3OC1-3 alkyl, C1-4 cyanoalkyl, C0-2(NR1R2)alkyl, C1-4-alkylCOOC1-4-alkyl, C1-4-alkylOCOC1-4-alkyl, C1-4-alkylNHCOC1-4-alkyl, C2-7 alkenyl, C2-7 alkynyl, CH2O-(CH2)1-3-OCH3; an optionally substituted C3-7 cycloalkyl; phenyl; C3-7 saturated or unsaturated heterocyclyl or heteroaryl group containing 1-4 heteroatom; R1 and R2 are independently selected from hydrogen, C1-7 alkyl or C1-6 alkanoyl group - and/or enantiomers and/or racemates and/or diastereomers and/or geometric isomers and/or pharmaceutically acceptable salts thereof formed with acids and bases, to the process for producing said compounds, to pharmaceutical compositions containing said compounds and to their use in the prevention and/or treatment of mGluR5 receptor-mediated disorders. |